SCHEMBL2533131

SCHEMBL2533131

COCCN(CCc1ccc(-c2cc3nccc(Oc4ccc(NC(=O)NC5CC5)cc4F)c3s2)nc1)C(=O)OC(C)(C)C

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MST1R Q04912 17/20 0.60
MET P08581 5/20 0.55
KDR P35968 5/20 0.55
AXL P30530 2/20 0.55
FLT3 P36888 2/20 0.55
NTRK1 P04629 1/20 0.55
KIT P10721 1/20 0.55
NTRK2 Q16620 1/20 0.55
PLK4 O00444 1/20 0.52
MAP4K4 O95819 1/20 0.52
ABL1 P00519 1/20 0.52
LCK P06239 1/20 0.52
FYN P06241 1/20 0.52
LYN P07948 1/20 0.52
HCK P08631 1/20 0.52
PDGFRB P09619 1/20 0.52
BCR P11274 1/20 0.52
SRC P12931 1/20 0.52
ABL2 P42684 1/20 0.52
FRK P42685 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12734243 0.94 MST1R (0.67) MST1RMETKDRAXLFLT3
SCHEMBL2535037 0.94 MST1R (0.59) MST1RMETKDRAXLFLT3
SCHEMBL12252239 0.92 MET (0.58) MST1RMETKDRAXLFLT3
SCHEMBL12734220 0.91 MST1R (0.63) MST1RMETKDRAXLFLT3
SCHEMBL2532441 0.91 MET (0.57) MST1RMETKDRAXLFLT3
SCHEMBL12252013 0.90 MET (0.56) MST1RMETKDRAXLFLT3
SCHEMBL14849142 0.89 MST1R (0.65) MST1RMETKDRAXLFLT3
SCHEMBL1479911 0.89 MST1R (0.59) MST1RMETKDRAXLFLT3
SCHEMBL12807207 0.88 MET (0.62) MST1RMETKDRAXLFLT3
SCHEMBL14840058 0.88 MST1R (0.65) MST1RMETKDRAXLFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8906852-B2 Inhibitors of protein tyrosine kinase activity METHYLGENE INC. (CA) 2014-12-09 US disclosed
US-8906852-B2 Inhibitors of protein tyrosine kinase activity METHYLGENE INC. (CA) 2014-12-09 US disclosed
US-20140315801-A1 METHODS OF TREATMENT OF CELL PROLIFERATIVE AND/OR OPHTHALMIC DISEASES, DISORDERS AND CONDITIONS USING INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY METHYLGENE INC (CA) 2014-10-23 US disclosed
US-20140315801-A1 METHODS OF TREATMENT OF CELL PROLIFERATIVE AND/OR OPHTHALMIC DISEASES, DISORDERS AND CONDITIONS USING INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY METHYLGENE INC (CA) 2014-10-23 US disclosed
US-20110257100-A1 Inhibitors of Protein Tyrosine Kinase Activity METHYLGENE INC. (CA) 2011-10-20 US disclosed
US-20110257100-A1 Inhibitors of Protein Tyrosine Kinase Activity METHYLGENE INC. (CA) 2011-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257100-A1 Inhibitors of Protein Tyrosine Kinase Activity ERBB2, ABL1, FLT1 MST1R 150/4885MET 138/4885KDR 5/4885
US-20140315801-A1 METHODS OF TREATMENT OF CELL PROLIFERATIVE AND/OR OPHTHALMIC DISEASES, DISORDERS AND CONDITIONS USING INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY FLT1, KDR, FLT4 MST1R 105/4885MET 49/4885KDR 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.